Flexion is a market leading monetisation tool for mobile application developers. It offers automated enabling of in-application billing and storefront integration. To date, Flexion has enabled thousands of individual products and served in excess of 100 million end-users. Our current list of customers include Hutchison 3G, Telefonica, Orange Group, Nokia, Sony Mobile, ZTE, Samsung. Flexion is used by most of the big mobile game publishers and service providers.

Company Growth (employees)
Type
Private
HQ
London, GB
Founded
2009
Size (employees)
33 (est)+7%
Flexion was founded in 2009 and is headquartered in London, GB

Key People/Management at Flexion

Jens Lauritzson

Jens Lauritzson

CEO
Richard Raynor

Richard Raynor

CTO
Per Lauritzson

Per Lauritzson

COO
Andreas MacMahon

Andreas MacMahon

CPO

Flexion Office Locations

Flexion has an office in London
London, GB (HQ)
103 Harbour Ave

Flexion Financials and Metrics

Summary Metrics

Founding Date

2009

Total Funding

$5.5 m

Latest funding size

$3 m

Time since last funding

over 1 year

Investors

Flexion's latest funding round in May 2016 was reported to be $3 m. In total, Flexion has raised $5.5 m

Flexion Financials

Flexion's revenue was reported to be £2.2 m in FY, 2014
GBP

Revenue (FY, 2014)

2.2 m

Gross profit (FY, 2014)

279.6 k

Gross profit margin (FY, 2014), %

13%

Net income (FY, 2014)

66.4 k

Cash (31-Mar-2016)

2.6 m
GBPFY, 2014

Revenue

2.2 m

Cost of goods sold

1.9 m

Gross profit

279.6 k

Gross profit Margin, %

13%
GBPFY, 2014FY, 2015FY, 2016

Cash

1.8 m1.4 m2.6 m

Accounts Receivable

138.5 k965.1 k752.6 k

Current Assets

2.8 m2.4 m3.4 m

PP&E

8.5 k5.7 k2 k
GBPFY, 2014

Income Taxes Paid

181.5 k
Y, 2016

Financial Leverage

1.2 x
Show all financial metrics

Traffic Overview of Flexion

Flexion Online and Social Media Presence

Flexion News and Updates

Hot to trot with Zilretta, Flexion rolls $100M-plus stock offering to fund the launch

Less than a week after winning FDA approval for its knee arthritis injection Zilretta—which analysts peg as a blockbuster standard-of-care med—Flexion is floating a $100 million-plus stock offering to fund the drug's rollout.

Flexion, Zilretta approval in hand, lays out roadmap to blockbuster launch

Flexion's Zilretta won approval on Friday, with its official label winning praise from executives and analysts. Some market watchers think it could climb into blockbuster sales territory.

Flexion Company Life and Culture

You may also be interested in